Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Revision History For: Intracel: Set to go Public on 2/16

No earlier versions found for this Subject.

Return to Intracel: Set to go Public on 2/16

Hoover's desciption:

Intracel is a drug development company focused on cancer vaccines, as well as immunotherapeutic and diagnostic products for cancers and infectious diseases. Most of Intracel's products are in clinical trials; colon cancer products OncoVAX(CL) and HumaSPECT are awaiting regulatory approval in the US and Europe. Through a partnership with Mentor, Intracel has also developed a bladder cancer treatment, which is in clinical trials. Intracel and Mentor are also allied on a bladder cancer test. Intracel subsidiary Bartels makes in vitro diagnostic products for viral and bacterial diseases; these are marketed to hospitals and clinical labs. Chairman Michael Hanna owns about 32% of the firm.